Literature DB >> 23134514

Factors that influence radioactive iodine use for thyroid cancer.

Maria Papaleontiou1, Mousumi Banerjee, Di Yang, James C Sisson, Ronald J Koenig, Megan R Haymart.   

Abstract

BACKGROUND: There is variation in the use of radioactive iodine (RAI) as treatment for well-differentiated thyroid cancer. The factors involved in physician decision-making for RAI remain unknown.
METHODS: We surveyed physicians involved in postsurgical management of patients with thyroid cancer from 251 hospitals. Respondents were asked to rate the factors important in influencing whether a thyroid cancer patient receives RAI. Multivariable analyses controlling for physician age, gender, specialty, case volume, and whether they personally administer RAI, were performed to determine correlates of importance placed on patients' and physicians' worry about death from cancer and differences between low- versus higher-case-volume physicians.
RESULTS: The survey response rate was 63% (534/853). Extent of disease, adequacy of surgical resection, patients' willingness to receive RAI, and patients' age were the factors physicians were most likely to report as quite or very important in influencing recommendations for RAI to patients with thyroid cancer. Interestingly, both physicians' and patients' worry about death from thyroid cancer were also important in determining RAI use. Physicians with less thyroid cancer cases per year were more likely than higher-volume physicians to report patients' (p<0.001) and physicians' worry about death (p=0.016) as quite or very important in decision-making. Other factors more likely to be of greater importance in determining RAI use for physicians with lower thyroid cancer patient volume versus higher include the accepted standard at the affiliated hospital (p=0.020), beliefs about RAI expressed by colleagues comanaging patients (p=0.003), and patient distance from the nearest facility administering RAI (p=0.012).
CONCLUSION: In addition to the extent of disease and adequacy of surgical resection, physicians place importance on physician and patient worry about death from thyroid cancer when deciding whether to treat a patient with RAI. The factors important to physician decision-making differ based on physician thyroid-cancer case-volume, with worry about death being more influential for low-case-volume physicians. As the mortality from thyroid cancer is low, the importance placed on death in decision making may be unwarranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23134514      PMCID: PMC3569922          DOI: 10.1089/thy.2012.0380

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  21 in total

1.  Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.

Authors:  Ian D Hay; William M McConahey; John R Goellner
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

2.  Thyroid cancer: is the incidence still increasing?

Authors:  Nicole C Hodgson; Jaclyn Button; Carmen C Solorzano
Journal:  Ann Surg Oncol       Date:  2004-12       Impact factor: 5.344

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Outcomes of patients with differentiated thyroid carcinoma following initial therapy.

Authors:  Jacqueline Jonklaas; Nicholas J Sarlis; Danielle Litofsky; Kenneth B Ain; S Thomas Bigos; James D Brierley; David S Cooper; Bryan R Haugen; Paul W Ladenson; James Magner; Jacob Robbins; Douglas S Ross; Monica Skarulis; Harry R Maxon; Steven I Sherman
Journal:  Thyroid       Date:  2006-12       Impact factor: 6.568

5.  A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004.

Authors:  Cairong Zhu; Tongzhang Zheng; Briseis A Kilfoy; Xuesong Han; Shuangge Ma; Yue Ba; Yana Bai; Rong Wang; Yong Zhu; Yawei Zhang
Journal:  Thyroid       Date:  2009-10       Impact factor: 6.568

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999.

Authors:  James P Burke; Ian D Hay; Fiona Dignan; John R Goellner; Sara J Achenbach; Ann L Oberg; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2005-06       Impact factor: 7.616

Review 8.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.

Authors:  Anna M Sawka; Lehana Thabane; Luciana Parlea; Irada Ibrahim-Zada; Richard W Tsang; James D Brierley; Sharon Straus; Shereen Ezzat; David P Goldstein
Journal:  Thyroid       Date:  2009-05       Impact factor: 6.568

9.  Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients.

Authors:  Eileen Huh Shinn; Cindy L Carmack Taylor; Kelly Kilgore; Alan Valentine; Diane C Bodurka; John Kavanagh; Anil Sood; Yisheng Li; Karen Basen-Engquist
Journal:  Palliat Support Care       Date:  2009-09

10.  Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.

Authors:  Yale D Podnos; David D Smith; Lawrence D Wagman; Joshua D I Ellenhorn
Journal:  J Surg Oncol       Date:  2007-07-01       Impact factor: 3.454

View more
  14 in total

1.  Thyroid cancer presentation and treatment in the United States.

Authors:  Lindsey Enewold; Linda C Harlan; Jennifer L Stevens; Elad Sharon
Journal:  Ann Surg Oncol       Date:  2014-11-01       Impact factor: 5.344

2.  Cancer-related worry in Canadian thyroid cancer survivors.

Authors:  Lauren Bresner; Rita Banach; Gary Rodin; Lehana Thabane; Shereen Ezzat; Anna M Sawka
Journal:  J Clin Endocrinol Metab       Date:  2014-11-13       Impact factor: 5.958

Review 3.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

4.  Worry in Thyroid Cancer Survivors with a Favorable Prognosis.

Authors:  Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart
Journal:  Thyroid       Date:  2019-07-25       Impact factor: 6.568

5.  Initial treatment patterns in younger adult patients with differentiated thyroid cancer in California.

Authors:  Thomas J Semrad; Alison M Semrad; D Gregory Farwell; Yingjia Chen; Rosemary Cress
Journal:  Thyroid       Date:  2015-03-23       Impact factor: 6.568

6.  Primary Care Provider Involvement in Thyroid Cancer Survivorship Care.

Authors:  Archana Radhakrishnan; David Reyes-Gastelum; Brittany Gay; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Lauren P Wallner; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

7.  Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer.

Authors:  James X Wu; Stephanie Young; Kevin Ro; Ning Li; Angela M Leung; Harvey K Chiu; Avital Harari; Michael W Yeh
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

8.  Prescribing Therapy for Hypothyroidism: Influence of Physician Characteristics.

Authors:  Jacqueline Jonklaas; Eshetu Tefera; Nawar Shara
Journal:  Thyroid       Date:  2018-12-17       Impact factor: 6.568

9.  Role of Patient Maximizing-Minimizing Preferences in Thyroid Cancer Surveillance.

Authors:  Joshua M Evron; David Reyes-Gastelum; Mousumi Banerjee; Laura D Scherer; Lauren P Wallner; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Brian J Zikmund-Fisher; Megan R Haymart
Journal:  J Clin Oncol       Date:  2019-10-01       Impact factor: 50.717

10.  Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.

Authors:  Lauren P Wallner; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Carrie Lubitz; Sarah T Hawley; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.